Manual Fractional Technology with CO₂ Laser Combined with Transdermal Drug Delivery for Hypertrophic Scar: A Retrospective Study.

IF 2 3区医学 Q2 SURGERY

Aesthetic Plastic Surgery Pub Date : 2025-04-02 DOI:10.1007/s00266-025-04837-5

Houhuang Qiu, Bingliang Wu, Fuqiang Pan, Siyuan Zhou, Liming Zhang, Xiang Zhou

{"title":"Manual Fractional Technology with CO2 Laser Combined with Transdermal Drug Delivery for Hypertrophic Scar: A Retrospective Study.","authors":"Houhuang Qiu, Bingliang Wu, Fuqiang Pan, Siyuan Zhou, Liming Zhang, Xiang Zhou","doi":"10.1007/s00266-025-04837-5","DOIUrl":null,"url":null,"abstract":"Background: Hypertrophic scars are a common fibrotic skin disorder with a high recurrence rate. While various treatment options exist, their efficacy remains uncertain. Manual fractional technology with CO2 laser technology, a novel approach, has shown promise; however, its effectiveness as a standalone ablative treatment is limited. This retrospective study aims to evaluate the clinical outcomes of combining Manual fractional technology with CO2 laser technology with triamcinolone acetonide and 5-fluorouracil transdermal delivery for the treatment of hypertrophic scars.Objective: This study retrospectively evaluated the clinical efficacy of MFT with CO2 laser combined with transdermal triamcinolone acetonide and 5-fluorouracil in treating hypertrophic scars.Methods: A cohort of 42 patients with 48 hypertrophic scars underwent the combination therapy thrice. Scar evaluations were conducted using the patient and observer scar assessment scale (POSAS) before treatment and one month after each session. Adverse and complication reactions were monitored, and patients were followed for 6 months post-treatment. Hypertrophic scar recurrence and patient satisfaction were assessed.Results: The total POSAS score significantly decreased from pre-treatment [48.00 (43.00, 53.75) VS 21.29±7.167; p<0.001]. In the subgroup analysis, treatment outcomes varied significantly by skin type, with scar quantity and genetic factors influencing remission time. The recurrence rate during the 6-month follow-up was 6.24%, with a satisfaction rate of 83.34%. No severe adverse reactions were reported.Conclusions: The findings indicate that laser-assisted drug delivery using MFT with CO2 laser demonstrates significant clinical efficacy, a low recurrence rate, and an absence of serious adverse reactions in treating hypertrophic scars. This method shows promise as a novel treatment modality for hypertrophic scars.Level of evidence iv: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .","PeriodicalId":7609,"journal":{"name":"Aesthetic Plastic Surgery","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic Plastic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00266-025-04837-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hypertrophic scars are a common fibrotic skin disorder with a high recurrence rate. While various treatment options exist, their efficacy remains uncertain. Manual fractional technology with CO₂ laser technology, a novel approach, has shown promise; however, its effectiveness as a standalone ablative treatment is limited. This retrospective study aims to evaluate the clinical outcomes of combining Manual fractional technology with CO₂ laser technology with triamcinolone acetonide and 5-fluorouracil transdermal delivery for the treatment of hypertrophic scars.

Objective: This study retrospectively evaluated the clinical efficacy of MFT with CO₂ laser combined with transdermal triamcinolone acetonide and 5-fluorouracil in treating hypertrophic scars.

Methods: A cohort of 42 patients with 48 hypertrophic scars underwent the combination therapy thrice. Scar evaluations were conducted using the patient and observer scar assessment scale (POSAS) before treatment and one month after each session. Adverse and complication reactions were monitored, and patients were followed for 6 months post-treatment. Hypertrophic scar recurrence and patient satisfaction were assessed.

Results: The total POSAS score significantly decreased from pre-treatment [48.00 (43.00, 53.75) VS 21.29±7.167; p<0.001]. In the subgroup analysis, treatment outcomes varied significantly by skin type, with scar quantity and genetic factors influencing remission time. The recurrence rate during the 6-month follow-up was 6.24%, with a satisfaction rate of 83.34%. No severe adverse reactions were reported.

Conclusions: The findings indicate that laser-assisted drug delivery using MFT with CO₂ laser demonstrates significant clinical efficacy, a low recurrence rate, and an absence of serious adverse reactions in treating hypertrophic scars. This method shows promise as a novel treatment modality for hypertrophic scars.

Level of evidence iv: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

查看原文本刊更多论文

背景：肥厚性疤痕是一种常见的纤维化皮肤病，复发率很高。虽然存在各种治疗方案，但其疗效仍不确定。手动点阵技术结合二氧化碳激光技术是一种新方法，已显示出良好的前景；但作为一种独立的消融治疗方法，其效果有限。这项回顾性研究旨在评估手动点阵技术与二氧化碳激光技术、曲安奈德和 5-氟尿嘧啶透皮给药相结合治疗增生性疤痕的临床效果：本研究回顾性评估了手动点阵技术与二氧化碳激光技术联合经皮曲安奈德和5-氟尿嘧啶治疗增生性疤痕的临床疗效：方法：42名患者共48处增生性疤痕接受了三次联合治疗。在治疗前和治疗后一个月，使用患者和观察者疤痕评估量表（POSAS）对疤痕进行评估。对不良反应和并发症进行了监测，并在治疗后对患者进行了为期 6 个月的随访。对肥厚性疤痕复发情况和患者满意度进行了评估：结果：POSAS总分较治疗前明显下降[48.00 (43.00, 53.75) VS 21.29±7.167；p结论：研究结果表明，在治疗增生性疤痕时，使用二氧化碳激光的 MFT 激光辅助给药具有明显的临床疗效，复发率低，且无严重不良反应。该方法有望成为增生性疤痕的新型治疗方式。证据级别iv：本期刊要求作者为每篇文章指定一个证据级别。有关这些循证医学评级的完整说明，请参阅目录或在线作者须知 www.springer.com/00266 。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aesthetic Plastic Surgery 医学-外科

CiteScore

4.40

自引率

25.00%

发文量

479

审稿时长

3 months

期刊介绍： Aesthetic Plastic Surgery is a publication of the International Society of Aesthetic Plastic Surgery and the official journal of the European Association of Societies of Aesthetic Plastic Surgery (EASAPS), Società Italiana di Chirurgia Plastica Ricostruttiva ed Estetica (SICPRE), Vereinigung der Deutschen Aesthetisch Plastischen Chirurgen (VDAPC), the Romanian Aesthetic Surgery Society (RASS), Asociación Española de Cirugía Estética Plástica (AECEP), La Sociedad Argentina de Cirugía Plástica, Estética y Reparadora (SACPER), the Rhinoplasty Society of Europe (RSE), the Iranian Society of Plastic and Aesthetic Surgeons (ISPAS), the Singapore Association of Plastic Surgeons (SAPS), the Australasian Society of Aesthetic Plastic Surgeons (ASAPS), the Egyptian Society of Plastic and Reconstructive Surgeons (ESPRS), and the Sociedad Chilena de Cirugía Plástica, Reconstructiva y Estética (SCCP). Aesthetic Plastic Surgery provides a forum for original articles advancing the art of aesthetic plastic surgery. Many describe surgical craftsmanship; others deal with complications in surgical procedures and methods by which to treat or avoid them. Coverage includes "second thoughts" on established techniques, which might be abandoned, modified, or improved. Also included are case histories; improvements in surgical instruments, pharmaceuticals, and operating room equipment; and discussions of problems such as the role of psychosocial factors in the doctor-patient and the patient-public interrelationships. Aesthetic Plastic Surgery is covered in Current Contents/Clinical Medicine, SciSearch, Research Alert, Index Medicus-Medline, and Excerpta Medica/Embase.